tiprankstipranks
Trending News
More News >
Inmed Pharmaceuticals Inc. (INM)
:INM
Advertisement

InMed Pharmaceuticals (INM) Price & Analysis

Compare
375 Followers

INM Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

19.32%<0.01%80.68%
19.32% Insiders
<0.01% Other Institutional Investors
80.68% Public Companies and Individual Investors

INM FAQ

What was Inmed Pharmaceuticals Inc.’s price range in the past 12 months?
Inmed Pharmaceuticals Inc. lowest stock price was $1.72 and its highest was $15.69 in the past 12 months.
    What is Inmed Pharmaceuticals Inc.’s market cap?
    Inmed Pharmaceuticals Inc.’s market cap is $5.35M.
      When is Inmed Pharmaceuticals Inc.’s upcoming earnings report date?
      Inmed Pharmaceuticals Inc.’s upcoming earnings report date is Sep 19, 2025 which is in 60 days.
        How were Inmed Pharmaceuticals Inc.’s earnings last quarter?
        Inmed Pharmaceuticals Inc. released its earnings results on May 12, 2025. The company reported -$1.94 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.94.
          Is Inmed Pharmaceuticals Inc. overvalued?
          According to Wall Street analysts Inmed Pharmaceuticals Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Inmed Pharmaceuticals Inc. pay dividends?
            Inmed Pharmaceuticals Inc. does not currently pay dividends.
            What is Inmed Pharmaceuticals Inc.’s EPS estimate?
            Inmed Pharmaceuticals Inc.’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Inmed Pharmaceuticals Inc. have?
            Inmed Pharmaceuticals Inc. has 2,002,186 shares outstanding.
              What happened to Inmed Pharmaceuticals Inc.’s price movement after its last earnings report?
              Inmed Pharmaceuticals Inc. reported an EPS of -$1.94 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 14.912%.
                Which hedge fund is a major shareholder of Inmed Pharmaceuticals Inc.?
                Currently, no hedge funds are holding shares in INM

                Company Description

                Inmed Pharmaceuticals Inc.

                InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
                Similar Stocks
                Company
                Price & Change
                Follow
                Galmed Pharmaceuticals
                Scinai Immunotherapeutics
                Revelation Biosciences
                GRI Bio
                Shuttle Pharmaceuticals Holdings, Inc.
                Popular Stocks
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis